How Palmitoyl Pentapeptide-4 Acts on the Skin: From the KTTKS Sequence and Skin Delivery to Collagen Matrix Responses

Introduction

Palmitoyl Pentapeptide-4 is a synthetic lipopeptide formed by linking a palmitoyl fatty-acyl chain to the pentapeptide KTTKS. Its International Nomenclature of Cosmetic Ingredients name is Palmitoyl Pentapeptide-4, and it is commonly referred to in research as Pal-KTTKS or C16-KTTKS.

KTTKS corresponds to a specific sequence within the carboxyl-terminal propeptide of the α1 chain of type I procollagen. Synthetic KTTKS can affect extracellular matrix synthesis by fibroblasts in vitro. Attachment of a palmitoyl group improves the molecule’s lipid affinity, skin deposition, and stability, making this hydrophilic short peptide more suitable for use in topical formulations.

Based on its history of research and application, Palmitoyl Pentapeptide-4 can be classified as one of the classic anti-aging signal peptides. Its principal function is not to directly replenish collagen, but to regulate extracellular matrix synthesis through the procollagen-derived KTTKS sequence. Its actual efficacy is also influenced by factors including skin delivery, molecular stability, release from the formulation, and duration of continuous use.

1 What Is the Structure of Palmitoyl Pentapeptide-4 Composed of?

1.1 KTTKS Represents Five Amino Acids

KTTKS is the one-letter sequence of five amino acids:

Letter	Amino Acid	Main Structural Feature
K	Lysine	The side chain contains a basic amino group and may carry a positive charge under common physiological conditions
T	Threonine	The side chain contains a hydroxyl group that can participate in hydrogen bonding
T	Threonine	Increases the polarity and hydrophilicity of the peptide chain
K	Lysine	Provides a second basic side chain
S	Serine	The side chain contains a hydroxyl group and is strongly hydrophilic

Unmodified KTTKS can be represented as:

Lys—Thr—Thr—Lys—Ser

Palmitoyl Pentapeptide-4 can be represented as:

Palmitoyl—Lys—Thr—Thr—Lys—Ser

The palmitoyl group is a saturated fatty-acyl chain containing 16 carbon atoms and is attached to the N-terminus of the peptide chain. The resulting molecule contains both a hydrophobic fatty-acyl chain and a hydrophilic peptide chain and is therefore an amphiphilic lipopeptide.

1.2 The Two Structural Components Perform Different Functions

The structure–function relationship of Palmitoyl Pentapeptide-4 can be summarized as follows:

Structural Component	Main Function
KTTKS pentapeptide sequence	Retains sequence information associated with procollagen processing and extracellular matrix regulation
C16 palmitoyl chain	Increases lipid affinity and alters skin distribution, molecular aggregation, and local stability
Amide linkage	Stably connects the fatty-acyl chain to the peptide chain and blocks the N-terminus of the peptide

KTTKS is the principal source of the bioactive sequence, whereas the palmitoyl chain mainly addresses issues related to topical delivery and molecular distribution. The palmitoyl chain itself cannot replace the sequence-specific activity of KTTKS, while KTTKS used alone is subject to substantial stratum corneum barrier and enzymatic degradation limitations.

2 Why Can KTTKS Act as a Matrix-Regulating Signal?

2.1 KTTKS Corresponds to a Specific Sequence in the Carboxyl-Terminal Propeptide of Type I Procollagen

Type I collagen synthesized by fibroblasts initially exists in the form of type I procollagen. Procollagen molecules contain an N-terminal propeptide and a C-terminal propeptide. These propeptides help maintain procollagen in a soluble state and reduce premature aggregation of collagen molecules within the cell.

After procollagen is secreted into the extracellular space, specific proteases remove the propeptides at both ends. The resulting collagen molecules then undergo further alignment, assembly, and crosslinking, gradually forming collagen fibrils and collagen fibers.

A 1993 study identified the KTTKS sequence within a fragment of the C-terminal propeptide of the α1 chain of type I procollagen. This pentapeptide corresponds to residues 212–216 of the propeptide region and can promote the production of type I collagen, type III collagen, and fibronectin by cultured fibroblasts [1].

KTTKS is therefore neither a typical Gly-X-Y repeat unit within the mature collagen triple helix nor a structural fragment directly used to assemble collagen fibers. It corresponds to a specific sequence within the C-terminal propeptide of type I procollagen, and synthetic KTTKS has demonstrated activity in regulating extracellular matrix synthesis in vitro.

2.2 KTTKS Mimics Information Associated with Procollagen Processing

The extracellular matrix (ECM) is composed of collagen, elastin, fibronectin, proteoglycans, and other components. It not only determines tissue structure and mechanical properties, but can also regulate cellular behavior through matrix fragments, cell-surface receptors, and mechanical interactions.

Certain bioactive peptide fragments derived from the extracellular matrix or its precursors may be referred to as matrix-derived regulatory peptides, or matrikines. These peptide fragments may influence cell migration, proliferation, differentiation, and matrix synthesis.

KTTKS mimics a specific sequence within the C-terminal propeptide of type I procollagen. When fibroblasts are exposed to this sequence, the synthesis of type I collagen, type III collagen, and fibronectin may change [1].

This activity is not equivalent to the complete wound-healing process. Wound healing also involves coagulation, recruitment of inflammatory cells, keratinocyte migration, angiogenesis, fibroblast activation, tissue contraction, and multiple other processes. Pal-KTTKS mainly participates in regulation related to matrix synthesis and remodeling and cannot independently reproduce the entire tissue-repair response.

A study using human dermal fibroblasts and three-dimensional collagen gels showed that 0.1 μmol/L Pal-KTTKS reduced α-smooth muscle actin (α-SMA)-positive stress fibers, fibroblast-to-myofibroblast differentiation, and collagen-gel contraction. At 0.5 μmol/L, some of these inhibitory effects were no longer evident [5]. These findings indicate that Pal-KTTKS does not unidirectionally enhance all wound-contraction responses and that its effects are influenced by concentration and cellular state.

3 How Does Palmitoylation Improve Skin Delivery?

3.1 Why Is It Difficult for Unmodified KTTKS to Cross the Stratum Corneum?

KTTKS contains two lysine residues, two threonine residues, and one serine residue. It has multiple hydroxyl groups, amino groups, and ionizable groups and is therefore highly hydrophilic overall.

The intercellular region of the stratum corneum, by contrast, is rich in ceramides, cholesterol, and free fatty acids. Hydrophilic or charged molecules, as well as molecules capable of forming strong hydrogen-bonding interactions, generally have difficulty partitioning from the aqueous phase of a formulation into this lipid-rich region.

KTTKS may also be degraded by peptidases and proteases present on the skin surface and within skin tissues. Skin-stability experiments have shown that both KTTKS and Pal-KTTKS undergo relatively rapid degradation in skin extracts and skin homogenates. The stability of both peptides was markedly increased by the addition of protease inhibitors [3].

Topically applied unmodified KTTKS therefore faces two main limitations:

1. A low capacity to partition from the aqueous phase into stratum corneum lipids;

2. Possible degradation by peptidases before reaching biologically active skin layers.

3.2 The Palmitoyl Chain Increases Lipid Affinity

The C16 palmitoyl chain increases the hydrophobicity of KTTKS, allowing Pal-KTTKS to redistribute among the aqueous phase, oil–water interfaces, surfactant aggregates, and stratum corneum lipids.

This change helps the molecule enter the stratum corneum, but it does not mean that it can pass through the entire skin without restriction.

Topically applied Pal-KTTKS must undergo a series of partitioning processes:

Aqueous phase or carrier in the formulation → oil–water interface of the formulation → intercellular lipids of the stratum corneum → aqueous environment of the viable epidermis → extracellular environment of the dermis

If molecular hydrophobicity is insufficient, only a limited proportion enters the stratum corneum. If lipid affinity is too strong, the molecule may instead remain trapped in the oil phase, micelles, or stratum corneum lipids. Palmitoylation improves the partitioning relationship among these environments.

3.3 Skin Experiments Indicate That Deposition Predominates

A 2014 ex vivo study compared the distribution of KTTKS and Pal-KTTKS in full-thickness hairless mouse skin. At the end of the experiment, neither peptide was detected in the receptor fluid, indicating that under the experimental conditions, neither peptide passed through the complete full-thickness skin.

Unmodified KTTKS was not detected in the stratum corneum, epidermis, or dermis. Pal-KTTKS was distributed across all three skin layers:

Skin Compartment	Pal-KTTKS Deposition
Stratum corneum	4.2 ± 0.7 μg/cm²
Epidermis	2.8 ± 0.5 μg/cm²
Dermis	0.3 ± 0.1 μg/cm²
Receptor fluid	Not detected

These results indicate that palmitoylation increased the deposition of KTTKS in the skin. Most of the deposited peptide was located in the stratum corneum and epidermis, whereas the amount detected in the dermis was relatively low [3].

The skin-delivery process of Palmitoyl Pentapeptide-4 can be represented as follows:

Release from the formulation

→ entry into stratum corneum lipids

→ deposition in the stratum corneum and epidermis

→ a small amount of the molecule enters the dermis

→ possible proximity to fibroblasts and their surrounding matrix

The experiment described above used ex vivo hairless mouse skin and a specific carrier and therefore cannot directly represent the actual distribution in human facial skin. Detection of a molecule within a particular skin layer also does not mean that all detected molecules remain structurally intact or retain the same biological activity.

4 What Happens After Pal-KTTKS Reaches Biologically Active Skin Layers?

4.1 The Principal Responses Involve Type I Collagen, Type III Collagen, and Fibronectin

Early research on KTTKS showed that this sequence could promote the production of type I collagen, type III collagen, and fibronectin by cultured fibroblasts [1].

Type I collagen is an abundant fibrillar collagen in the dermis and mainly contributes to tensile strength and structural support.

Type III collagen is commonly distributed together with type I collagen, contributes to the formation of finer reticular fibers, and is associated with tissue renewal and early repair.

Fibronectin is not a collagen protein but an extracellular matrix adhesive glycoprotein. It can interact with cell-surface receptors, collagen, and proteoglycans and participates in cell adhesion, migration, and the organization of newly formed matrix.

A 2013 study further examined the effects of C16-KTTKS on collagen production by human dermal fibroblasts and human corneal fibroblasts. The results showed that collagen responses were associated with the concentration and self-assembled state of C16-KTTKS [2].

4.2 TGF-β-Related Regulation May Participate in Type I Collagen Expression

Transforming growth factor-β (TGF-β) is an important cytokine that regulates fibroblast function and extracellular matrix synthesis.

A study using rat tendon cells showed that non-palmitoylated KTTKS increased type I collagen protein expression, increased messenger RNA expression of α1(I) procollagen and TGF-β, and slowed the degradation of existing α1(I) procollagen messenger RNA. TGF-β concentrations in the culture medium also increased with the dose of KTTKS treatment [4].

These results support the following regulatory relationship:

KTTKS treatment

→ increased expression and stability of α1(I) procollagen messenger RNA

→ increased type I collagen protein expression

The following changes were also observed:

Increased TGF-β messenger RNA expression and increased TGF-β concentration in the culture medium

This study used rat tendon cells and non-palmitoylated KTTKS. It indicates that TGF-β-related regulation may participate in the activity of KTTKS, but the findings do not confirm that increased TGF-β is the direct cause of improved procollagen messenger RNA stability. Nor can they be directly equated with a fully established Pal-KTTKS signaling pathway in human skin.

4.3 Current Research on Direct Receptors and Intracellular Signaling Pathways

Fibroblasts can recognize collagen, fibronectin, and other extracellular matrix components through integrins. Once activated, integrins can also regulate focal adhesion kinase, the cytoskeleton, and signaling networks such as mitogen-activated protein kinase (MAPK).

Core studies of Pal-KTTKS have observed changes in collagen production, collagen expression, cellular contraction, and self-assembled states, but they have not confirmed that Pal-KTTKS directly binds to a particular integrin. Publicly available studies also lack the following evidence:

① Direct binding experiments between Pal-KTTKS and purified integrins;

② Identification of a specific receptor subtype and binding constant;

③ Loss of Pal-KTTKS activity following integrin blockade or gene knockdown;

④ Structural evidence of a complex formed between Pal-KTTKS and a specific receptor.

MAPK is broadly involved in fibroblast proliferation, stress responses, collagen expression, and matrix degradation. Existing studies have likewise not established a confirmed continuous “Pal-KTTKS–integrin–focal adhesion kinase–MAPK” pathway [1–5].

5 How Does Increased Collagen Expression Translate into Changes in Skin Appearance?

5.1 Newly Synthesized Procollagen Must Still Undergo Maturation

After fibroblasts increase the expression of collagen-related genes or proteins, newly synthesized procollagen must still undergo multiple steps:

1. Synthesis of procollagen α chains;

2. Hydroxylation of proline and lysine residues;

3. Formation of the triple helix;

4. Secretion of procollagen into the extracellular space;

5. Removal of the N-terminal and C-terminal propeptides;

6. Alignment of collagen molecules and fibril assembly;

7. Crosslinking of collagen fibers;

8. Re-establishment of dynamic equilibrium with matrix-degradation processes.

An increase in collagen expression in cellular experiments therefore represents an early stage of matrix remodeling and does not mean that mature collagen fibers increase immediately.

5.2 Skin Condition Depends on the Net Balance Between Synthesis and Degradation

Dermal collagen is continuously undergoing synthesis, assembly, and degradation. Ultraviolet radiation, chronic inflammation, and oxidative stress can promote the expression of matrix metalloproteinases and accelerate collagen degradation.

Existing Pal-KTTKS studies have mainly focused on indicators related to matrix synthesis and the regulation of fibroblast phenotypes. Whether measurable structural changes ultimately occur also depends on:

① Whether newly synthesized procollagen completes maturation;

② Whether collagen fibers undergo normal assembly and crosslinking;

③ Whether the rate of collagen degradation is simultaneously increased;

④ Whether the skin remains continuously exposed to ultraviolet radiation and inflammatory stimuli;

⑤ Whether the duration of use is sufficient for matrix renewal to occur.

6 Why Does Formulation Processing Affect Actual Efficacy?

6.1 Raw-Material Addition Level and Active Peptide Concentration Are Different Concepts

Commercial peptide ingredients are commonly supplied as premixed solutions containing water, glycerol, glycols, and preservative systems. Adding a particular percentage of the raw-material solution to a formulation does not mean that the finished product contains the same percentage of Pal-KTTKS.

Assessment of the actual dose in the finished product requires the following concepts to be distinguished:

Concentration Concept	Meaning
Raw-material addition level	Percentage of the peptide raw-material solution added during production
Active peptide content of the raw material	Actual mass percentage of Pal-KTTKS in the raw-material solution
Theoretical concentration in the finished product	Pal-KTTKS concentration calculated from the raw-material content and addition level
Measured concentration in the finished product	Concentration of intact Pal-KTTKS detected after production and storage
Effective concentration in the skin	Concentration of intact and bioavailable molecules released from the formulation and delivered to the site of action

6.2 Self-Assembly Alters the Proportion of Free Peptide

Pal-KTTKS contains a hydrophobic palmitoyl chain and a hydrophilic peptide chain and can form nanoribbons, micelles, or other aggregated structures. A 2013 study showed that the collagen-stimulating activity of C16-KTTKS was associated with its concentration and self-assembly behavior [2].

In a finished product, Pal-KTTKS may exist in different states: free monomers; small peptide aggregates; nanoribbon-like or micelle-like structures; adsorption on the surfaces of emulsifier aggregates; partitioning into oil droplets or phospholipid bilayers; or interactions with charged polymers.

The aggregation state may alter the proportion of free peptide, diffusion, and release behavior. Consequently, an identical total content in the finished product does not necessarily indicate identical skin availability, which must still be verified in the specific formulation.

6.3 Carriers Must Balance Protection and Release

Phospholipid vesicles, liposomes, and other colloidal carriers can be used to improve the dispersion and stability of Pal-KTTKS.

A 2024 study incorporated N-palmitoyl KTTKS into phosphatidylcholine liposomal membranes and observed a relatively pronounced collagen-production response from liposome-delivered Pal-KTTKS in a mouse fibroblast model [7]. The study showed that the presentation state within liposomes can alter the collagen-production response of Pal-KTTKS in an in vitro fibroblast model, but it did not directly demonstrate improved delivery through human skin or increased cellular uptake.

6.4 Production and Storage Conditions Require Verification in the Finished Product

The state of Pal-KTTKS in an actual formulation may be influenced by temperature, pH, emulsifiers, electrolytes, thickening polymers, and preservative systems.

During production, the stage of addition should be determined using raw-material information and finished-product testing to reduce unnecessary exposure to high temperatures. During storage, the following should be evaluated:

① Remaining content of intact Pal-KTTKS molecules;

② Changes in formulation appearance and particle size;

③ Precipitation or irreversible aggregation;

④ Compatibility with packaging materials;

⑤ Stability under different temperature and light conditions.

A stable formulation appearance cannot substitute for evaluation of active peptide content, release capacity, and skin deposition.

7 Human Studies and Actual Product Efficacy

7.1 Existing Human Research Supports the Potential to Improve Fine Lines

A randomized, double-blind, vehicle-controlled, split-face study enrolled 93 women aged 35–55 years. Participants used the products continuously for 12 weeks, applying a basic moisturizing formulation to one side of the face and the same basic formulation containing 3 ppm Pal-KTTKS to the other side.

A concentration of 3 ppm corresponds to 0.0003% active Pal-KTTKS. Skin changes were assessed by quantitative image analysis, expert grading, and participant self-assessment. Quantitative image analysis and expert grading showed that the Pal-KTTKS-containing formulation outperformed the base formulation for fine-line- and wrinkle-related parameters at certain time points and was well tolerated [6].

This study indicates that under a specific formulation, dose, and duration of use, Pal-KTTKS has the potential to improve the appearance of fine lines in photoaged facial skin.

At the same time, the study evaluated a complete finished product rather than the Pal-KTTKS molecule in isolation. The appearance of wrinkles is also affected by multiple factors, including stratum corneum hydration, surface smoothness, the optical properties of the skin, and dermal structure. Improvements in appearance cannot be directly converted into a quantified increase in any particular type of collagen within the human dermis.

7.2 How to Evaluate Pal-KTTKS in a Product

When evaluating a product containing Palmitoyl Pentapeptide-4, the following information can be considered:

① Confirm the specific ingredient name.

Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, and Palmitoyl Tripeptide-38 contain different peptide sequences and cannot be substituted for one another.

② Distinguish between the proportion of the raw-material solution and the concentration of the pure peptide.

“Addition of 1% peptide raw material” does not mean that the product contains 1% Pal-KTTKS.

③ Consider studies conducted on the finished product.

Cellular experiments on a single raw material cannot directly represent a finished product. Studies using the same base formulation as a control, a clearly defined duration of use, and instrument-based measurements provide greater reference value.

④ Consider the duration of use.

Collagen production, secretion, and fiber remodeling require time. The smoothing effect caused by short-term moisturization should be evaluated separately from long-term matrix regulation.

⑤ Combine use with sun protection and barrier care.

Ultraviolet radiation can continuously promote collagen degradation. Reducing photodamage, maintaining stratum corneum stability, and regulating matrix synthesis together influence long-term skin condition.

8 Classification and Research Applications of Representative Chemicals Related to Palmitoyl Pentapeptide-4 Structural Construction, Skin Delivery, Collagen Matrix Responses, and Signaling Pathway Studies

Table 1 Products Related to KTTKS Sequence Construction, Palmitoylation, and Solid-Phase Peptide Synthesis

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Peptide-chain cleavage and side-chain deprotection reagent	76-05-1	T103293	Trifluoroacetic acid (TFA)	For protein sequencing, ≥99%	Used for peptide cleavage from resin, removal of acid-labile side-chain protecting groups, and preparation of crude Palmitoyl Pentapeptide-4 in solid-phase peptide synthesis.
KTTKS serine monomer	56-45-1	S137887	L-Serine	Animal-free, USP, Moligand™, European Pharmacopoeia (Ph. Eur.), ≥98.5%	Used for KTTKS sequence-composition studies, amino acid reference analysis, peptide hydrolysate analysis, and research related to serine residues.
Raw material for N-terminal palmitoylation	57-10-3	P432957	Palmitic acid	Suitable for synthesis, Moligand™	Used for N-terminal C16 fatty acylation of the KTTKS peptide chain, regulation of lipid affinity, screening of palmitoylation conditions, and structural confirmation of the product.
Fmoc deprotection reagent	110-89-4	P1506346	Piperidine (controlled precursor chemical)	Biotechnology grade, ≥99.5%	Used for stepwise deprotection and KTTKS peptide-chain elongation in fluorenylmethoxycarbonyl-based solid-phase peptide synthesis.
Organic base for peptide-bond coupling	7087-68-5	D109322	N,N-Diisopropylethylamine	Distillation grade, ≥99.5%	Used for basicity adjustment, acid scavenging, and reaction-condition optimization in peptide-bond coupling and N-terminal palmitoylation reactions.
KTTKS threonine monomer	72-19-5	L433393	L-Threonine	UltraBio™, ultrapure grade, ≥99.5% (NT)	Used for KTTKS sequence-composition studies, amino acid reference analysis, peptide-chain hydrolysis analysis, and structural studies of threonine residues.
KTTKS lysine monomer	56-87-1	L598932	L-Lysine	Moligand™, ≥98%, metals <500 ppm	Used for KTTKS sequence-composition studies, lysine side-chain reactions, peptide-chain hydrolysis analysis, and charge-property studies.
Peptide-bond coupling reagent	148893-10-1	H109327	O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU)	≥99%	Used for carboxyl activation of protected amino acids, solid-phase coupling of the KTTKS peptide chain, and coupling of palmitic acid to the peptide N-terminus.
Protected serine building block	71989-33-8	F116797	Fmoc-O-tert-butyl-L-serine	≥98%	Used to introduce C-terminal or internal serine residues during solid-phase synthesis of KTTKS while protecting the serine side-chain hydroxyl group.
Protected threonine building block	71989-35-0	F110979	Fmoc-O-tert-butyl-L-threonine	≥98%	Used to construct consecutive threonine residues during solid-phase synthesis of KTTKS and to reduce side reactions involving side-chain hydroxyl groups.
Protected lysine building block	71989-26-9	F110978	Nα-Fluorenylmethoxycarbonyl-Nε-tert-butoxycarbonyl-L-lysine	≥98%	Used for selective protection of lysine residues, directional peptide-chain elongation, and studies of conditions for constructing the KTTKS sequence.

Table 2 Products Related to Collagen, Fibronectin, and Extracellular Matrix Maturation and Degradation Studies

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Type III collagen matrix model	9007-34-5	rp335221	Recombinant Humanized Type III Collagen Protein	Animal-free, carrier-free, recombinant, ≥90% (SDS-PAGE), expressed in Nicotiana benthamiana	Used as a reference for type III collagen detection and structural analysis, for extracellular matrix model construction, fibroblast culture, and development of collagen-related analytical methods.
Fibronectin matrix model	86088-83-7	rp146053	Recombinant Human Fibronectin Fragment Protein	Animal-free, carrier-free, biologically active, ActiBioPure™, high-performance, sterile, His-tagged, PBS only, ≥98% (SDS-PAGE)	Used for fibroblast adhesion, fibronectin-related matrix-response studies, and cell-coating experiments.
Denatured collagen structural reference	9000-70-8	G108395	Gelatin	Suitable for microbiology, gel strength approximately 250 g Bloom	Used for comparison of native and denatured collagen structures, gel formation, matrix degradation, and studies of the physical properties of collagen proteins.
Collagen-degradation model enzyme	9001-12-1	C754914	Collagenase from Clostridium histolyticum	Sterile-filtered, Type IA-S, 0.5–5.0 FALGPA units/mg solid, ≥125 CDU/mg solid	Used for collagen degradation, extracellular matrix remodeling, collagen-stability evaluation, and studies of matrix resistance to degradation before and after peptide treatment.
Collagen amino acid structural reference	147-85-3	L476193	L-Proline	UltraBio™, ≥99.5%	Used for studies of collagen amino acid composition, proline hydroxylation, collagen sequence characteristics, and nutrient conditions in cell culture.
Collagen hydroxylation-product standard	51-35-4	H111005	L-Hydroxyproline	Moligand™, ≥99%	Used for collagen-content determination, preparation of hydroxyproline standard curves, analysis of collagen-degradation products, and quantitative analysis of tissue matrix.
Collagen-hydroxylation cofactor	50-81-7	L432793	L-Ascorbic acid	Anhydrous grade, Moligand™, ACS, ≥99%	Used to maintain iron in the reduced state at the active sites of collagen hydroxylases, support procollagen maturation, and study collagen production by fibroblasts.
Collagen-hydroxylation cosubstrate	328-50-7	K105571	α-Ketoglutaric acid	Moligand™, ≥98%	Used in prolyl hydroxylase and lysyl hydroxylase reactions, procollagen hydroxylation, and studies of dioxygenase activity.
Ferrous-ion source for collagen hydroxylation	7782-63-0	I434044	Iron(II) sulfate heptahydrate	European Pharmacopoeia (Ph. Eur.), suitable for analysis, ACS, guaranteed reagent grade	Used in ferrous-ion-dependent collagen hydroxylase reactions, screening of metal-ion conditions, and enzymatic studies related to procollagen maturation.
Copper-ion source for collagen crosslinking	7758-99-8	C433966	Copper(II) sulfate pentahydrate	European Pharmacopoeia (Ph. Eur.), suitable for analysis, ACS, guaranteed reagent grade	Used for studies of the copper dependence of lysyl oxidase, collagen and elastin crosslinking, and comparison of metal-ion conditions.

Table 3 Products Related to Collagen Deposition, Staining, and Quantitative Hydroxyproline Analysis

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Hydroxyproline color-development reagent	100-10-7	D278973	4-Dimethylaminobenzaldehyde	≥98%	Used for colorimetric detection of hydroxyproline, collagen-content determination, analysis of matrix production in cell culture, and quantitative analysis of tissue collagen.
Collagen-staining and quantification reagent	2610-10-8	D278961	Direct Red 80	Dye content 25%	Used for collagen-fiber staining, observation of extracellular matrix deposition, semiquantitative determination of total collagen, and evaluation of collagen-network morphology.
Hydroxyproline oxidation reagent	7080-50-4	C104061	Chloramine-T trihydrate	AR, ≥98% (T)	Used for hydroxyproline oxidation, colorimetric determination of collagen hydrolysates, and analysis of collagen content in tissues or cell-derived matrices.

Table 4 Products Related to Lipid Delivery and Validation of Candidate Signaling Pathways

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Phospholipid carrier material	8002-43-5	P1456010	Phospholipids from sunflower, non-GMO	Natural, with ≥60% phosphatidylcholine	Used for construction of Palmitoyl Pentapeptide-4 liposomes, phospholipid vesicles, and skin-delivery models, as well as encapsulation, release, and stability studies.
Liposomal-membrane stabilizing component	57-88-5	C432975	Cholesterol from lanolin	PharmPure™, JP, BP, European Pharmacopoeia (Ph. Eur.), NF, ultrapure grade	Used to regulate phospholipid-membrane fluidity, liposome stability, the encapsulation state of Palmitoyl Pentapeptide-4, and carrier-release behavior.
Transforming growth factor-β receptor pathway validation	301836-41-9	S1371574-GMP	SB-431542	Moligand™, ≥99%	Used to block ALK4-, ALK5-, and ALK7-related signaling, evaluate changes in collagen expression, and investigate candidate pathways involved in KTTKS activity.
p38 mitogen-activated protein kinase pathway validation	152121-47-6	S131899	SB-203580, p38 MAPK inhibitor	Moligand™, ≥98% (HPLC)	Used to inhibit p38 mitogen-activated protein kinase-related signaling and to study fibroblast stress responses and mechanisms of collagen expression.
MEK1/2–ERK pathway validation	109511-58-2	U274745	U0126, MKK inhibitor	Moligand™, ≥98%	Used to inhibit MEK1/2 activity, block ERK1/2 signaling, and investigate cell proliferation and candidate pathways involved in collagen matrix responses.
Focal adhesion kinase pathway validation	869288-64-2	P129814	PF-573228, FAK inhibitor	≥98%	Used to inhibit focal adhesion kinase-related signaling and to study fibroblast adhesion, mechanosensing, and candidate pathways involved in matrix responses.
RGD-binding integrin adhesion-competition control peptide	91037-65-9	A101721	Arginine-glycine-aspartic acid-serine	≥95% (HPLC)	Used for competitive studies of cell adhesion mediated by RGD-binding integrins, fibronectin recognition, and evaluation of whether related integrins participate in cellular responses to Pal-KTTKS.

Note: The products listed above are representative Aladdin products related to scientific research and formulation studies. Additional product specifications, grades, and certificates of analysis can be retrieved from the Aladdin website using the product name, CAS number, or catalog number.

References

[1] Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry. 1993;268(14):9941–9944. DOI: 10.1016/S0021-9258(18)82153-6.

[2] Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Molecular Pharmaceutics. 2013;10(3):1063–1069. DOI: 10.1021/mp300549d.

[3] Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomolecules & Therapeutics. 2014;22(4):321–327. DOI: 10.4062/biomolther.2014.053.

[4] Tsai WC, Hsu CC, Chung CY, Lin MS, Li SL, Pang JHS. The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-β of tendon cells. Journal of Orthopaedic Research. 2007;25(12):1629–1634. DOI: 10.1002/jor.20455.

[5] Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Engineering and Regenerative Medicine. 2017;14(1):73–80. DOI: 10.1007/s13770-016-0017-y.

[6] Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155–160. DOI: 10.1111/j.1467-2494.2005.00261.x.

[7] Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl–KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. DOI: 10.3390/pharmaceutics16020219.

For more related articles, see below:

Analysis of Hydrolyzed Pearl as a Cosmetic Raw Material: Preparation Process, Active Components, and Skincare Formulation Applications

The Dual-Targeted Skin-Brightening Mechanism of 4-MSK: Inhibiting Melanin Production and Reducing Epidermal Pigment Retention

Antioxidant Mechanisms, Stability, and Delivery Strategies of Resveratrol in Skincare Research

Antioxidant Mechanisms of Ferulic Acid in Skincare, Vitamin C/E Synergy, and Stable Delivery Applications

Tocopherols in the Vitamin E Family: How They Block the Chain Reaction of Lipid Peroxidation in Skin Lipids

The Skin Anti-Aging Mechanisms of α-Lipoic Acid: ALA/DHLA Redox Cycling, the Antioxidant Network, and Regulation of Collagen AGE Formation

Mechanistic Analysis of Topical Glutathione in Skincare: Cellular Redox Regulation, Skin Delivery Challenges, and SLN-Based Delivery Strategies

Mechanism of Kojic Acid in Reducing Hyperpigmentation: From Tyrosinase Inhibition to Melanin Production Regulation

Beneath the Skin: Protein- and Peptide-Based Actives in Skincare and Aesthetic Medicine

Understanding Ceramides from the Perspective of the Stratum Corneum Lipid Barrier: Moisturizing and Barrier-Repair Mechanisms, Ingredient Selection, and Formulation Research Considerations

Hyaluronidase: Unlocking a “Magic Enzyme” in Biomedicine

Hyaluronan

Recombinant Humanized Type III Collagen: Structural Basis, Manufacturing Technologies, and Dermatological Applications

Trehalose: Physicochemical Characteristics, Manufacturing Processes, and Application Guidelines

Compounds found in Green Tea

Sources, Biological Functions, Isolation/Characterization, and Emerging Applications of Exosomes

Applicability Comparison of Vitronectin, Laminin and Fibronectin in Cell Culture Coating Systems

Cosmetic Peptides

Resveratrol

Ferulic Acid: Structural Features, Preparation Routes, and Key Points for Research Applications

Role of Sphingolipid Metabolic Remodeling in Apoptotic and Inflammatory Signaling

Cosmetic Grade Explained

How to decipher the whitening code?

Niacin (Vitamin B3): Structural Features, Metabolic Roles, and Application Landscape

The "Six Key Checkpoints" of Skin Lightening

Tyrosinase: a key regulatory enzyme in melanin synthesis and its biological and applied significance

Glutathione (GSH) Quantification: Method Systems, Experimental Workflows, and Key Quality-Control Considerations

Glutathione Reductase: A Flavin-Dependent Reductive System Maintaining GSH/GSSG Homeostasis, with Assays and Applications

What is Glutathione？

What Is Glutathione Agarose?

Enzymatic Hydroxylation Mechanism of Salicylate Conversion to Catechol